A note for UK readers

This page explains Ireland’s system. Its licences, funding rules and prescribing criteria do not determine access in the UK.

Does the latest Wegovy reimbursement recommendation mean it is covered now?

No. The NCPE recommendation goes to the HSE for a separate decision; it is not an individual funding entitlement.

A consultation comes first

The HSE describes Wegovy as a treatment for obesity or qualifying overweight, with a prescription and clinical assessment. It separately describes Ozempic as a diabetes treatment. Coverage for diabetes should not be carried across to weight management.

Read the HSE position

The HSE patient page checked for this guide says Wegovy is not covered by the medical card, Long-Term Illness Scheme or Drugs Payment Scheme. Ask the prescriber or pharmacy to confirm whether a later HSE decision changes your position.

A recent assessment is not the final step

In October 2026 the NCPE recommended considering Wegovy for reimbursement, while highlighting substantial budget impact. Its published next step is HSE consideration. Headlines about that recommendation should not be treated as a funded start date.

What this means for UK readers

The Irish decision is useful context for access debates, but it does not change NHS funding. HSE schemes apply in the Republic of Ireland; Northern Ireland has a separate UK health-service pathway. An Irish recommendation should not be reported as UK access.

Keep these four questions separate

Access

Irish prescribing pathway; not UK eligibility

Funding

HSE decision separate from NCPE recommendation

Cost context

EUR context; not a UK NHS or private-care price

Regulatory source

HPRA; EU authorisation framework

Compare health systems ↗
Follow the evidence

Sources & further reading

Sources checked . These links support the information above; they do not imply endorsement of this website.

  1. HSE: medicines to treat obesity
  2. NCPE: Wegovy assessment completed October 2026
A note on this guide

Written for a UK audience by the Health Comparisons editorial team. This page is an information resource and has not been presented as a clinician’s personal recommendation. Discuss treatment decisions with your prescriber.

Read our editorial standards →